US Stock MarketDetailed Quotes
TNXP Tonix Pharmaceuticals
- 0.1924
- +0.0024+1.26%
Trading Nov 25 14:02 ET
35.96MMarket Cap-2P/E (TTM)
0.2111High0.1860Low35.13MVolume0.1947Open0.1900Pre Close6.95MTurnover18.80%Turnover Ratio0.00P/E (Static)186.89MShares22.137652wk High0.48P/B35.96MFloat Cap0.118052wk Low--Dividend TTM186.89MShs Float263679868.1600Historical High--Div YieldTTM13.21%Amplitude0.1180Historical Low0.1970Avg Price1Lot Size
Tonix Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 19.60%-18.8M | 57.55%-9.92M | 46.60%-17.58M | -4.03%-102M | -0.17%-22.34M | 0.64%-23.39M | -10.37%-23.37M | -6.01%-32.91M | -29.77%-98.05M | 0.64%-22.3M |
| Net income from continuing operations | 49.19%-14.21M | -177.81%-78.78M | 54.74%-14.94M | -5.84%-116.66M | 13.76%-27.32M | 3.47%-27.98M | -22.54%-28.36M | -24.94%-33.01M | -19.43%-110.22M | -7.20%-31.68M |
| Operating gains losses | --0 | --855K | ---7.01M | --221K | --417K | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -58.06%510K | 30.84%1.21M | 35.50%1.21M | 242.46%4.29M | 50.84%1.26M | 382.54%1.22M | 802.94%921K | 1,317.46%893K | 2,406.00%1.25M | 2,996.30%836K |
| Other non cash items | --209K | --129K | --302K | --903K | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | -544.33%-6.63M | 182.81%4.82M | 132.42%1.17M | -1,650.00%-35K | -93.77%363K | -38.62%1.49M | 280.13%1.7M | 50.86%-3.59M | -100.03%-2K | 21.78%5.83M |
| -Change in receivables | -5.19%-1.64M | ---- | ---- | ---- | ---- | ---1.56M | ---- | ---- | ---- | ---- |
| -Change in inventory | --1.25M | --1.16M | --1.29M | --61K | --61K | --0 | --0 | --0 | --0 | ---- |
| -Change in prepaid assets | -111.12%-341K | 60.52%2.37M | -12.35%-1.36M | 1,059.15%1.57M | -398.98%-1.76M | -15.49%3.07M | 166.55%1.47M | 44.32%-1.21M | -131.66%-164K | -66.05%589K |
| -Change in payables and accrued expense | -19,506.67%-5.88M | 2,028.44%4.64M | 151.64%1.23M | -1,165.00%-1.7M | -90.65%490K | 97.50%-30K | -82.78%218K | 53.70%-2.38M | -96.97%160K | 71.78%5.24M |
| -Change in other current liabilities | ---- | ---- | ---- | 1,650.00%35K | ---- | ---- | ---- | ---- | --2K | ---3K |
| -Change in other working capital | -135.29%-6K | -133.33%-4K | 140.00%2K | ---- | ---- | --17K | 300.00%12K | -400.00%-5K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 19.60%-18.8M | 57.55%-9.92M | 46.60%-17.58M | -4.03%-102M | -0.17%-22.34M | 0.64%-23.39M | -10.37%-23.37M | -6.01%-32.91M | -29.77%-98.05M | 0.64%-22.3M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 98.90%-9K | 0 | 97.16%-108K | 39.62%-29.07M | 90.77%-431K | 90.69%-821K | -66.35%-24.02M | 81.21%-3.8M | -36.37%-48.15M | 81.77%-4.67M |
| Net PPE purchase and sale | 98.90%-9K | --0 | 97.16%-108K | 85.68%-6.9M | 90.77%-431K | 90.69%-821K | 87.22%-1.85M | 81.21%-3.8M | -36.37%-48.15M | 81.77%-4.67M |
| Net business purchase and sale | --0 | ---- | ---- | ---22.17M | --0 | --0 | ---- | ---- | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 98.90%-9K | --0 | 97.16%-108K | 39.62%-29.07M | 90.77%-431K | 90.69%-821K | -66.35%-24.02M | 81.21%-3.8M | -36.37%-48.15M | 81.77%-4.67M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 583.85%42.91M | 582.70%7.03M | 98.16%-212K | -58.43%36.52M | 463.20%40.71M | 235.65%6.27M | -98.57%1.03M | -188.03%-11.5M | -58.66%87.84M | -83.48%7.23M |
| Net issuance payments of debt | ---705K | ---705K | ---235K | --8.94M | --8.94M | --0 | --0 | --0 | --0 | ---- |
| Net common stock issuance | 595.03%43.61M | 942.76%10.73M | --0 | -94.73%4.97M | -4.49%9.2M | -76.65%6.27M | -97.71%1.03M | -188.53%-11.53M | -55.52%94.46M | -77.99%9.63M |
| Net preferred stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---6.66M | ---2.4M |
| Proceeds from stock option exercised by employees | --4K | --0 | -20.69%23K | -27.50%29K | --0 | --0 | --0 | -27.50%29K | -59.18%40K | --0 |
| Net other financing activities | --0 | ---- | ---- | --22.57M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 583.85%42.91M | 582.70%7.03M | 98.16%-212K | -58.43%36.52M | 463.20%40.71M | 235.65%6.27M | -98.57%1.03M | -188.03%-11.5M | -58.66%87.84M | -83.48%7.23M |
| Net cash flow | ||||||||||
| Beginning cash position | -80.44%5.06M | -88.99%7.95M | -78.54%25.85M | -32.66%120.47M | -94.35%7.92M | -85.41%25.86M | -48.66%72.22M | -32.66%120.47M | 131.41%178.9M | -23.47%140.22M |
| Current changes in cash | 234.37%24.1M | 93.76%-2.89M | 62.88%-17.9M | -62.03%-94.56M | 190.88%17.94M | 51.51%-17.93M | -226.77%-46.36M | -26.20%-48.21M | -157.42%-58.36M | -359.14%-19.74M |
| Effect of exchange rate changes | -41.67%-17K | --1K | 90.70%-4K | 12.16%-65K | -100.00%-10K | 40.00%-12K | --0 | -72.00%-43K | -138.71%-74K | 50.00%-5K |
| End cash Position | 268.06%29.14M | -80.44%5.06M | -88.99%7.95M | -78.54%25.85M | -78.54%25.85M | -94.35%7.92M | -85.41%25.86M | -48.66%72.22M | -32.66%120.47M | -32.66%120.47M |
| Free cash flow | 25.35%-18.81M | 60.66%-9.92M | 51.83%-17.68M | 24.83%-109.9M | 15.55%-22.78M | 22.12%-25.2M | 29.20%-25.21M | 28.39%-36.71M | -31.87%-146.2M | 43.89%-26.97M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
